Figure 9From: Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathwaysEffects of MET inhibition on p53-null tumour-derived cell lines. (A) Effect of the Met tyrosine kinase inhibitor (TKI) PHA-665752 on cellular tyrosine phosphorylation in different p53-null tumour-derived cell lines. Cell lysates were subjected to Western blot analysis as indicated. (B) and (C) Effect of Met inhibition on proliferation of cells with low (tumour cell line 1201, B) and high (tumour cell line 1204, C) levels of Met gene amplification. IB, Immunoblot.Back to article page